Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B
Lamivudine and interferon have been widely used for the treatment of patients with chronic HBV infection. Serum HBV RNA is detected during lamivudine therapy as a consequence of interrupted reverse transcription and because RNA replicative intermediates are unaffected by the drug. In this study, we...
Gespeichert in:
| Veröffentlicht in: | Antiviral therapy 2010-01, Vol.15 (2), p.177-184 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 184 |
|---|---|
| container_issue | 2 |
| container_start_page | 177 |
| container_title | Antiviral therapy |
| container_volume | 15 |
| creator | HUANG, Yi-Wen CHAYAMA, Kazuaki YANG, Sien-Sing KAO, Jia-Horng TSUGE, Masataka TAKAHASHI, Shoichi HATAKEYAMA, Tsuyoshi ABE, Hiromi HU, Jui-Ting LIU, Chun-Jen LAI, Ming-Yang CHEN, Ding-Shinn |
| description | Lamivudine and interferon have been widely used for the treatment of patients with chronic HBV infection. Serum HBV RNA is detected during lamivudine therapy as a consequence of interrupted reverse transcription and because RNA replicative intermediates are unaffected by the drug. In this study, we aimed to determine the detectability of serum HBV RNA during sequential combination therapy of interferon and lamivudine.
HBV DNA and RNA in serum samples were quantified by reverse transcription of HBV nucleic acid extract and real-time PCR. Samples were analysed every 2 weeks to 3 months from three groups of patients: 10 male patients treated with nucleoside analogue monotherapy for 44-48 weeks (5 with lamivudine and 5 with entecavir), 6 males on sequential interferon and lamivudine combination therapy, and 3 males on lamivudine monotherapy for 20-24 weeks.
HBV RNA was not detectable in any patients before treatment, but became detectable in 15 during antiviral treatment. Among the three groups, pre-treatment HBV DNA (8.1 +/-2.4 versus 7.7 +/-1.4 versus 5.1 +/-0.3 log(10) copies/ml; P=0.06), treatment and follow-up durations (45.5 +/-2.0 versus 49.7 +/-5.6 versus 48.7 +/-6.4 weeks; P=0.32) were comparable. HBV RNA was detectable at the end of treatment or follow-up in all patients with monotherapy, but in none of those with sequential combination therapy (100% versus 0%; P |
| doi_str_mv | 10.3851/IMP1508 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733880467</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733880467</sourcerecordid><originalsourceid>FETCH-LOGICAL-c310t-4b03263355efb01e47262bf29b1f624f8b6401f2148278a455b9759e24dffc9a3</originalsourceid><addsrcrecordid>eNpFkMlOwzAURS0EomUQf4C8QawCz1PiLMvYSkxCwDZyXFs1ylBsB8Tf44pCV-_p3qOzuAgdEThjUpDz2f0TESC30JgCh4yCkNtoTJgos1wwMUJ7IbwDUFkC7KIRBSZzKOgY-StnrfGmi0412KRfx4B7i10XjU9N32HVzXGjWvc5zF1ncEqC8UOLpxdv-PlhktCFq110qXAdXqroki7gLxcXWC-SwWm8MKs8uoAvDtCOVU0wh-u7j15vrl8up9nd4-3scnKXaUYgZrwGRnPGhDC2BmJ4QXNaW1rWxOaUW1nnHIilhEtaSMWFqMtClIbyubW6VGwfnf56l77_GEyIVeuCNk2jOtMPoSoYkxJ4XmxI7fsQvLHV0rtW-e-KQLXat1rvm8jjtXOoWzP_5_4GTcDJGlBBq8Z61WkXNhwtciZowX4AdB-BuA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733880467</pqid></control><display><type>article</type><title>Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B</title><source>MEDLINE</source><source>Sage Journals GOLD Open Access 2024</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>HUANG, Yi-Wen ; CHAYAMA, Kazuaki ; YANG, Sien-Sing ; KAO, Jia-Horng ; TSUGE, Masataka ; TAKAHASHI, Shoichi ; HATAKEYAMA, Tsuyoshi ; ABE, Hiromi ; HU, Jui-Ting ; LIU, Chun-Jen ; LAI, Ming-Yang ; CHEN, Ding-Shinn</creator><creatorcontrib>HUANG, Yi-Wen ; CHAYAMA, Kazuaki ; YANG, Sien-Sing ; KAO, Jia-Horng ; TSUGE, Masataka ; TAKAHASHI, Shoichi ; HATAKEYAMA, Tsuyoshi ; ABE, Hiromi ; HU, Jui-Ting ; LIU, Chun-Jen ; LAI, Ming-Yang ; CHEN, Ding-Shinn</creatorcontrib><description>Lamivudine and interferon have been widely used for the treatment of patients with chronic HBV infection. Serum HBV RNA is detected during lamivudine therapy as a consequence of interrupted reverse transcription and because RNA replicative intermediates are unaffected by the drug. In this study, we aimed to determine the detectability of serum HBV RNA during sequential combination therapy of interferon and lamivudine.
HBV DNA and RNA in serum samples were quantified by reverse transcription of HBV nucleic acid extract and real-time PCR. Samples were analysed every 2 weeks to 3 months from three groups of patients: 10 male patients treated with nucleoside analogue monotherapy for 44-48 weeks (5 with lamivudine and 5 with entecavir), 6 males on sequential interferon and lamivudine combination therapy, and 3 males on lamivudine monotherapy for 20-24 weeks.
HBV RNA was not detectable in any patients before treatment, but became detectable in 15 during antiviral treatment. Among the three groups, pre-treatment HBV DNA (8.1 +/-2.4 versus 7.7 +/-1.4 versus 5.1 +/-0.3 log(10) copies/ml; P=0.06), treatment and follow-up durations (45.5 +/-2.0 versus 49.7 +/-5.6 versus 48.7 +/-6.4 weeks; P=0.32) were comparable. HBV RNA was detectable at the end of treatment or follow-up in all patients with monotherapy, but in none of those with sequential combination therapy (100% versus 0%; P<0.001).
Compared with lamivudine therapy with detectable serum HBV RNA in patients with chronic HBV infection, interferon treatment might reduce HBV DNA replication through the inhibition of HBV RNA replicative intermediates, resulting in the loss of serum HBV RNA.</description><identifier>ISSN: 1359-6535</identifier><identifier>EISSN: 2040-2058</identifier><identifier>DOI: 10.3851/IMP1508</identifier><identifier>PMID: 20386072</identifier><language>eng</language><publisher>London: International Medical Press</publisher><subject><![CDATA[Adult ; Aged ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Antiviral Agents - administration & dosage ; Antiviral Agents - pharmacology ; Biological and medical sciences ; DNA, Viral - blood ; Drug Administration Schedule ; Drug Therapy, Combination ; Guanine - administration & dosage ; Guanine - analogs & derivatives ; Guanine - pharmacology ; Hepatitis B, Chronic - drug therapy ; Hepatitis B, Chronic - virology ; Human viral diseases ; Humans ; Infectious diseases ; Interferons - administration & dosage ; Interferons - pharmacology ; Lamivudine - administration & dosage ; Lamivudine - pharmacology ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Reverse Transcriptase Inhibitors - administration & dosage ; Reverse Transcriptase Inhibitors - pharmacology ; RNA, Viral - blood ; RNA, Viral - drug effects ; Treatment Outcome ; Viral diseases ; Viral hepatitis]]></subject><ispartof>Antiviral therapy, 2010-01, Vol.15 (2), p.177-184</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c310t-4b03263355efb01e47262bf29b1f624f8b6401f2148278a455b9759e24dffc9a3</citedby><cites>FETCH-LOGICAL-c310t-4b03263355efb01e47262bf29b1f624f8b6401f2148278a455b9759e24dffc9a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22763527$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20386072$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HUANG, Yi-Wen</creatorcontrib><creatorcontrib>CHAYAMA, Kazuaki</creatorcontrib><creatorcontrib>YANG, Sien-Sing</creatorcontrib><creatorcontrib>KAO, Jia-Horng</creatorcontrib><creatorcontrib>TSUGE, Masataka</creatorcontrib><creatorcontrib>TAKAHASHI, Shoichi</creatorcontrib><creatorcontrib>HATAKEYAMA, Tsuyoshi</creatorcontrib><creatorcontrib>ABE, Hiromi</creatorcontrib><creatorcontrib>HU, Jui-Ting</creatorcontrib><creatorcontrib>LIU, Chun-Jen</creatorcontrib><creatorcontrib>LAI, Ming-Yang</creatorcontrib><creatorcontrib>CHEN, Ding-Shinn</creatorcontrib><title>Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B</title><title>Antiviral therapy</title><addtitle>Antivir Ther</addtitle><description>Lamivudine and interferon have been widely used for the treatment of patients with chronic HBV infection. Serum HBV RNA is detected during lamivudine therapy as a consequence of interrupted reverse transcription and because RNA replicative intermediates are unaffected by the drug. In this study, we aimed to determine the detectability of serum HBV RNA during sequential combination therapy of interferon and lamivudine.
HBV DNA and RNA in serum samples were quantified by reverse transcription of HBV nucleic acid extract and real-time PCR. Samples were analysed every 2 weeks to 3 months from three groups of patients: 10 male patients treated with nucleoside analogue monotherapy for 44-48 weeks (5 with lamivudine and 5 with entecavir), 6 males on sequential interferon and lamivudine combination therapy, and 3 males on lamivudine monotherapy for 20-24 weeks.
HBV RNA was not detectable in any patients before treatment, but became detectable in 15 during antiviral treatment. Among the three groups, pre-treatment HBV DNA (8.1 +/-2.4 versus 7.7 +/-1.4 versus 5.1 +/-0.3 log(10) copies/ml; P=0.06), treatment and follow-up durations (45.5 +/-2.0 versus 49.7 +/-5.6 versus 48.7 +/-6.4 weeks; P=0.32) were comparable. HBV RNA was detectable at the end of treatment or follow-up in all patients with monotherapy, but in none of those with sequential combination therapy (100% versus 0%; P<0.001).
Compared with lamivudine therapy with detectable serum HBV RNA in patients with chronic HBV infection, interferon treatment might reduce HBV DNA replication through the inhibition of HBV RNA replicative intermediates, resulting in the loss of serum HBV RNA.</description><subject>Adult</subject><subject>Aged</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - administration & dosage</subject><subject>Antiviral Agents - pharmacology</subject><subject>Biological and medical sciences</subject><subject>DNA, Viral - blood</subject><subject>Drug Administration Schedule</subject><subject>Drug Therapy, Combination</subject><subject>Guanine - administration & dosage</subject><subject>Guanine - analogs & derivatives</subject><subject>Guanine - pharmacology</subject><subject>Hepatitis B, Chronic - drug therapy</subject><subject>Hepatitis B, Chronic - virology</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Interferons - administration & dosage</subject><subject>Interferons - pharmacology</subject><subject>Lamivudine - administration & dosage</subject><subject>Lamivudine - pharmacology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Reverse Transcriptase Inhibitors - administration & dosage</subject><subject>Reverse Transcriptase Inhibitors - pharmacology</subject><subject>RNA, Viral - blood</subject><subject>RNA, Viral - drug effects</subject><subject>Treatment Outcome</subject><subject>Viral diseases</subject><subject>Viral hepatitis</subject><issn>1359-6535</issn><issn>2040-2058</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkMlOwzAURS0EomUQf4C8QawCz1PiLMvYSkxCwDZyXFs1ylBsB8Tf44pCV-_p3qOzuAgdEThjUpDz2f0TESC30JgCh4yCkNtoTJgos1wwMUJ7IbwDUFkC7KIRBSZzKOgY-StnrfGmi0412KRfx4B7i10XjU9N32HVzXGjWvc5zF1ncEqC8UOLpxdv-PlhktCFq110qXAdXqroki7gLxcXWC-SwWm8MKs8uoAvDtCOVU0wh-u7j15vrl8up9nd4-3scnKXaUYgZrwGRnPGhDC2BmJ4QXNaW1rWxOaUW1nnHIilhEtaSMWFqMtClIbyubW6VGwfnf56l77_GEyIVeuCNk2jOtMPoSoYkxJ4XmxI7fsQvLHV0rtW-e-KQLXat1rvm8jjtXOoWzP_5_4GTcDJGlBBq8Z61WkXNhwtciZowX4AdB-BuA</recordid><startdate>20100101</startdate><enddate>20100101</enddate><creator>HUANG, Yi-Wen</creator><creator>CHAYAMA, Kazuaki</creator><creator>YANG, Sien-Sing</creator><creator>KAO, Jia-Horng</creator><creator>TSUGE, Masataka</creator><creator>TAKAHASHI, Shoichi</creator><creator>HATAKEYAMA, Tsuyoshi</creator><creator>ABE, Hiromi</creator><creator>HU, Jui-Ting</creator><creator>LIU, Chun-Jen</creator><creator>LAI, Ming-Yang</creator><creator>CHEN, Ding-Shinn</creator><general>International Medical Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100101</creationdate><title>Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B</title><author>HUANG, Yi-Wen ; CHAYAMA, Kazuaki ; YANG, Sien-Sing ; KAO, Jia-Horng ; TSUGE, Masataka ; TAKAHASHI, Shoichi ; HATAKEYAMA, Tsuyoshi ; ABE, Hiromi ; HU, Jui-Ting ; LIU, Chun-Jen ; LAI, Ming-Yang ; CHEN, Ding-Shinn</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c310t-4b03263355efb01e47262bf29b1f624f8b6401f2148278a455b9759e24dffc9a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - administration & dosage</topic><topic>Antiviral Agents - pharmacology</topic><topic>Biological and medical sciences</topic><topic>DNA, Viral - blood</topic><topic>Drug Administration Schedule</topic><topic>Drug Therapy, Combination</topic><topic>Guanine - administration & dosage</topic><topic>Guanine - analogs & derivatives</topic><topic>Guanine - pharmacology</topic><topic>Hepatitis B, Chronic - drug therapy</topic><topic>Hepatitis B, Chronic - virology</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Interferons - administration & dosage</topic><topic>Interferons - pharmacology</topic><topic>Lamivudine - administration & dosage</topic><topic>Lamivudine - pharmacology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Reverse Transcriptase Inhibitors - administration & dosage</topic><topic>Reverse Transcriptase Inhibitors - pharmacology</topic><topic>RNA, Viral - blood</topic><topic>RNA, Viral - drug effects</topic><topic>Treatment Outcome</topic><topic>Viral diseases</topic><topic>Viral hepatitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HUANG, Yi-Wen</creatorcontrib><creatorcontrib>CHAYAMA, Kazuaki</creatorcontrib><creatorcontrib>YANG, Sien-Sing</creatorcontrib><creatorcontrib>KAO, Jia-Horng</creatorcontrib><creatorcontrib>TSUGE, Masataka</creatorcontrib><creatorcontrib>TAKAHASHI, Shoichi</creatorcontrib><creatorcontrib>HATAKEYAMA, Tsuyoshi</creatorcontrib><creatorcontrib>ABE, Hiromi</creatorcontrib><creatorcontrib>HU, Jui-Ting</creatorcontrib><creatorcontrib>LIU, Chun-Jen</creatorcontrib><creatorcontrib>LAI, Ming-Yang</creatorcontrib><creatorcontrib>CHEN, Ding-Shinn</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Antiviral therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HUANG, Yi-Wen</au><au>CHAYAMA, Kazuaki</au><au>YANG, Sien-Sing</au><au>KAO, Jia-Horng</au><au>TSUGE, Masataka</au><au>TAKAHASHI, Shoichi</au><au>HATAKEYAMA, Tsuyoshi</au><au>ABE, Hiromi</au><au>HU, Jui-Ting</au><au>LIU, Chun-Jen</au><au>LAI, Ming-Yang</au><au>CHEN, Ding-Shinn</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B</atitle><jtitle>Antiviral therapy</jtitle><addtitle>Antivir Ther</addtitle><date>2010-01-01</date><risdate>2010</risdate><volume>15</volume><issue>2</issue><spage>177</spage><epage>184</epage><pages>177-184</pages><issn>1359-6535</issn><eissn>2040-2058</eissn><abstract>Lamivudine and interferon have been widely used for the treatment of patients with chronic HBV infection. Serum HBV RNA is detected during lamivudine therapy as a consequence of interrupted reverse transcription and because RNA replicative intermediates are unaffected by the drug. In this study, we aimed to determine the detectability of serum HBV RNA during sequential combination therapy of interferon and lamivudine.
HBV DNA and RNA in serum samples were quantified by reverse transcription of HBV nucleic acid extract and real-time PCR. Samples were analysed every 2 weeks to 3 months from three groups of patients: 10 male patients treated with nucleoside analogue monotherapy for 44-48 weeks (5 with lamivudine and 5 with entecavir), 6 males on sequential interferon and lamivudine combination therapy, and 3 males on lamivudine monotherapy for 20-24 weeks.
HBV RNA was not detectable in any patients before treatment, but became detectable in 15 during antiviral treatment. Among the three groups, pre-treatment HBV DNA (8.1 +/-2.4 versus 7.7 +/-1.4 versus 5.1 +/-0.3 log(10) copies/ml; P=0.06), treatment and follow-up durations (45.5 +/-2.0 versus 49.7 +/-5.6 versus 48.7 +/-6.4 weeks; P=0.32) were comparable. HBV RNA was detectable at the end of treatment or follow-up in all patients with monotherapy, but in none of those with sequential combination therapy (100% versus 0%; P<0.001).
Compared with lamivudine therapy with detectable serum HBV RNA in patients with chronic HBV infection, interferon treatment might reduce HBV DNA replication through the inhibition of HBV RNA replicative intermediates, resulting in the loss of serum HBV RNA.</abstract><cop>London</cop><pub>International Medical Press</pub><pmid>20386072</pmid><doi>10.3851/IMP1508</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1359-6535 |
| ispartof | Antiviral therapy, 2010-01, Vol.15 (2), p.177-184 |
| issn | 1359-6535 2040-2058 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733880467 |
| source | MEDLINE; Sage Journals GOLD Open Access 2024; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Aged Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Antiviral Agents - administration & dosage Antiviral Agents - pharmacology Biological and medical sciences DNA, Viral - blood Drug Administration Schedule Drug Therapy, Combination Guanine - administration & dosage Guanine - analogs & derivatives Guanine - pharmacology Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - virology Human viral diseases Humans Infectious diseases Interferons - administration & dosage Interferons - pharmacology Lamivudine - administration & dosage Lamivudine - pharmacology Male Medical sciences Middle Aged Pharmacology. Drug treatments Reverse Transcriptase Inhibitors - administration & dosage Reverse Transcriptase Inhibitors - pharmacology RNA, Viral - blood RNA, Viral - drug effects Treatment Outcome Viral diseases Viral hepatitis |
| title | Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T21%3A21%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Differential%20effects%20of%20interferon%20and%20lamivudine%20on%20serum%20HBV%20RNA%20inhibition%20in%20patients%20with%20chronic%20hepatitis%20B&rft.jtitle=Antiviral%20therapy&rft.au=HUANG,%20Yi-Wen&rft.date=2010-01-01&rft.volume=15&rft.issue=2&rft.spage=177&rft.epage=184&rft.pages=177-184&rft.issn=1359-6535&rft.eissn=2040-2058&rft_id=info:doi/10.3851/IMP1508&rft_dat=%3Cproquest_cross%3E733880467%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733880467&rft_id=info:pmid/20386072&rfr_iscdi=true |